340 related articles for article (PubMed ID: 10694292)
21. Serum and salivary desmoglein 1 and 3 enzyme-linked immunosorbent assay in pemphigus vulgaris: correlation with phenotype and severity.
Hallaji Z; Mortazavi H; Lajevardi V; Tamizifar B; AmirZargar A; Daneshpazhooh M; Chams-Davatchi C
J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):275-80. PubMed ID: 19709345
[TBL] [Abstract][Full Text] [Related]
22. Comparison of diagnostic value of indirect immunofluorescence assay and desmoglein ELISA in the diagnosis of pemphigus.
Marinović B; Fabris Z; Lipozencić J; Stulhofer Buzina D; Lakos Jukić I
Acta Dermatovenerol Croat; 2010; 18(2):79-83. PubMed ID: 20624356
[TBL] [Abstract][Full Text] [Related]
23. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile.
Amagai M; Tsunoda K; Zillikens D; Nagai T; Nishikawa T
J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):167-70. PubMed ID: 10025740
[TBL] [Abstract][Full Text] [Related]
24. Pemphigus vulgaris localized to the nose and cheeks.
Baykal C; Azizlerli G; Thoma-Uszynski S; Hertl M
J Am Acad Dermatol; 2002 Dec; 47(6):875-80. PubMed ID: 12451372
[TBL] [Abstract][Full Text] [Related]
25. Pemphigus vulgaris: recent advances in our understanding of its pathogenesis.
Femiano F
Minerva Stomatol; 2007 Apr; 56(4):215-23. PubMed ID: 17452959
[TBL] [Abstract][Full Text] [Related]
26. Detection of IgA autoantibodies to desmogleins by an enzyme-linked immunosorbent assay: the presence of new minor subtypes of IgA pemphigus.
Hashimoto T; Komai A; Futei Y; Nishikawa T; Amagai M
Arch Dermatol; 2001 Jun; 137(6):735-8. PubMed ID: 11405762
[TBL] [Abstract][Full Text] [Related]
27. Immune response towards the amino-terminus of desmoglein 1 prevails across different activity stages in nonendemic pemphigus foliaceus.
Chan PT; Ohyama B; Nishifuji K; Yoshida K; Ishii K; Hashimoto T; Amagai M
Br J Dermatol; 2010 Jun; 162(6):1242-50. PubMed ID: 20163417
[TBL] [Abstract][Full Text] [Related]
28. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.
Eming R; Rech J; Barth S; Kalden JR; Schuler G; Harrer T; Hertl M
Dermatology; 2006; 212(2):177-87. PubMed ID: 16484825
[TBL] [Abstract][Full Text] [Related]
29. Herpetiform pemphigus showing reactivity with pemphigus vulgaris antigen (desmoglein 3).
Kubo A; Amagai M; Hashimoto T; Doi T; Higashiyama M; Hashimoto K; Yoshikawa K
Br J Dermatol; 1997 Jul; 137(1):109-13. PubMed ID: 9274636
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of commercially available ELISA assays as a tool for monitoring and managing pemphigus patients: a prospective study.
Bracke S; Speeckaert R; Van Geel N; De Bacquer D; Lambert J
Eur J Dermatol; 2013; 23(1):33-9. PubMed ID: 23302186
[TBL] [Abstract][Full Text] [Related]
31. The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay.
Komai A; Amagai M; Ishii K; Nishikawa T; Chorzelski T; Matsuo I; Hashimoto T
Br J Dermatol; 2001 Jun; 144(6):1177-82. PubMed ID: 11422038
[TBL] [Abstract][Full Text] [Related]
32. Decline of anti-desmoglein 1 IgG ELISA scores by withdrawal of D-penicillamine in drug-induced pemphigus foliaceus.
Nagao K; Tanikawa A; Yamamoto N; Amagai M
Clin Exp Dermatol; 2005 Jan; 30(1):43-5. PubMed ID: 15663502
[TBL] [Abstract][Full Text] [Related]
33. Anti-desmoglein 1 antibodies in Tunisian healthy subjects: arguments for the role of environmental factors in the occurrence of Tunisian pemphigus foliaceus.
Kallel Sellami M; Ben Ayed M; Mouquet H; Drouot L; Zitouni M; Mokni M; Cerruti M; Turki H; Fezza B; Mokhtar I; Ben Osman A; Zahaf A; Kamoun MR; Joly P; Masmoudi H; Makni S; Tron F; Gilbert D
Clin Exp Immunol; 2004 Jul; 137(1):195-200. PubMed ID: 15196262
[TBL] [Abstract][Full Text] [Related]
34. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels.
Harman KE; Seed PT; Gratian MJ; Bhogal BS; Challacombe SJ; Black MM
Br J Dermatol; 2001 Apr; 144(4):775-80. PubMed ID: 11298536
[TBL] [Abstract][Full Text] [Related]
35. Three cases of transition from pemphigus vulgaris to pemphigus foliaceus confirmed by desmoglein ELISA.
Ng PP; Thng ST
Dermatology; 2005; 210(4):319-21. PubMed ID: 15942219
[TBL] [Abstract][Full Text] [Related]
36. Detection of anti-envoplakin and anti-periplakin autoantibodies by ELISA in patients with paraneoplastic pemphigus.
Huang Y; Li J; Zhu X
Arch Dermatol Res; 2009 Oct; 301(10):703-9. PubMed ID: 18820940
[TBL] [Abstract][Full Text] [Related]
37. Development of pemphigus vulgaris in a patient with pemphigus foliaceus: antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay.
Ishii K; Amagai M; Ohata Y; Shimizu H; Hashimoto T; Ohya K; Nishikawa T
J Am Acad Dermatol; 2000 May; 42(5 Pt 2):859-61. PubMed ID: 10767686
[TBL] [Abstract][Full Text] [Related]
38. Comparison of desmoglein 1 and 3 enzyme-linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris.
Daneshpazhooh M; Kamyab K; Kalantari MS; Balighi K; Naraghi ZS; Shamohammadi S; Mortazavizadeh SM; Ramezani A; Chams-Davatchi C
Clin Exp Dermatol; 2014 Jan; 39(1):41-7. PubMed ID: 23782219
[TBL] [Abstract][Full Text] [Related]
39. Correlation of immunological profile with phenotype and disease outcome in pemphigus.
Herrero-González JE; Iranzo P; Benítez D; Lozano F; Herrero C; Mascaró JM
Acta Derm Venereol; 2010 Jul; 90(4):401-5. PubMed ID: 20574606
[TBL] [Abstract][Full Text] [Related]
40. DSG 3 and DSG 1-ELISA as a specific diagnostic tool in oral bullous diseases.
Sistig S; Lukac J; Vucicevic-Boras V; Malenica B
Eur J Med Res; 2002 Apr; 7(4):181-2. PubMed ID: 12017158
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
